Abstract
Objective: A phase II trial was conducted to evaluate the efficacy and toxicity of belotecan (CKD-602), a topoisomerase I inhibitor, in persistent or recurrent carcinoma of the cervix.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
